We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

127 hedge funds and large institutions have $872M invested in Avidity Biosciences in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,513% more call options, than puts

Call options by funds: $2.31M | Put options by funds: $24K

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

39% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 31

15% more capital invested

Capital invested by funds: $757M → $872M (+$115M)

10% more funds holding

Funds holding: 115 → 127 (+12)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.33% less ownership

Funds ownership: 104.79% → 102.46% (-2.3%)

Holders
127
Holders Change
+12
Holders Change %
+10.43%
% of All Funds
2.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
43
Reduced
31
Closed
13
Calls
$2.31M
Puts
$24K
Net Calls
+$2.28M
Net Calls Change
-$1.18M

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$29.2M
2
APM
Avidity Partners Management
Texas
+$9.94M
3
Goldman Sachs
Goldman Sachs
New York
+$8.33M
4
RI
RTW Investments
New York
+$7.19M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$5.28M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$51.9M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$16.6M
3
Alkeon Capital Management
Alkeon Capital Management
New York
-$12.4M
4
GPP
Great Point Partners
Connecticut
-$7.26M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
26
Artal Group
Luxembourg
$4.08M – – –
AWA
27
Aaron Wealth Advisors
Illinois
$3.52M – – –
CS
28
Candriam SCA
Luxembourg
$3.45M – – –
Wellington Management Group
29
Wellington Management Group
Massachusetts
$3.24M -$16.6M -869,930 -81%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.87M +$364K +19,046 +12%
Barclays
31
Barclays
United Kingdom
$2.77M +$760K +39,730 +31%
ACM
32
Altium Capital Management
New York
$2.45M – – –
Invesco
33
Invesco
Georgia
$2.41M +$2.15M +112,540 +321%
N
34
Nuveen
North Carolina
$2.33M -$782K -40,897 -22%
Deutsche Bank
35
Deutsche Bank
Germany
$2.31M +$312K +16,292 +13%
TD Asset Management
36
TD Asset Management
Ontario, Canada
$2.23M +$15.3K +800 +0.6%
Rafferty Asset Management
37
Rafferty Asset Management
New York
$2.21M +$1.72M +90,108 +200%
Renaissance Technologies
38
Renaissance Technologies
New York
$2.02M +$300K +15,700 +14%
AllianceBernstein
39
AllianceBernstein
Tennessee
$1.95M -$2.93M -152,923 -56%
JP Morgan Chase
40
JP Morgan Chase
New York
$1.81M -$296K -15,461 -12%
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.52M -$9.24K -483 -0.5%
Swiss National Bank
42
Swiss National Bank
Switzerland
$1.45M +$101K +5,300 +6%
Morgan Stanley
43
Morgan Stanley
New York
$1.31M -$1.03M -53,649 -40%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$1.26M +$151K +7,876 +11%
US Bancorp
45
US Bancorp
Minnesota
$1.23M -$964K -50,370 -40%
Bank of America
46
Bank of America
North Carolina
$1.12M +$270K +14,090 +26%
Citigroup
47
Citigroup
New York
$1.11M +$228K +11,916 +21%
TCM
48
Tekla Capital Management
Massachusetts
$1.05M -$394K -20,600 -24%
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$989K +$834K +43,604 +257%
Balyasny Asset Management
50
Balyasny Asset Management
Illinois
$934K -$2.48M -129,495 -69%
1
2
3 4 5

RNAM Hedge Fund Activity: Q3 2022 in Review

127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q3 2022, worth a combined $872M — up 15% from $757M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RNAM positions and 13 closed out — a net gain of 12 holders — while 43 added to existing stakes and 31 trimmed.

The largest buyer was Cowen and Company, adding an estimated $29.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $51.9M.

  • 127 institutional investors held Avidity Biosciences (RNAM) as of Q3 2022, up from 115 in Q2 2022.
  • Funds reported $872M of Avidity Biosciences stock for Q3 2022, up 15% quarter-over-quarter.
  • 25 funds opened new Avidity Biosciences positions in Q3 2022 and 13 closed out, a net change of +12 holders.
  • The largest Avidity Biosciences buyer in Q3 2022 was Cowen and Company, an estimated $29.2M added.
  • The largest Avidity Biosciences seller in Q3 2022 was T. Rowe Price Associates, an estimated $51.9M sold.

Based on aggregated 13F filings for Q3 2022.